The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

MAD2L1BP  -  MAD2L1 binding protein

Homo sapiens

Synonyms: CMT2, Caught by MAD2 protein, KIAA0110, MAD2L1-binding protein, dJ261G23.1
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MAD2L1BP

  • BACKGROUND: Linkage analysis studies have identified 3 genetically different varieties of hereditary motor and sensory neuropathy type 2 (HMSN 2, also called Charcot-Marie-Tooth disease type 2, or CMT 2): HMSN 2A (linked to 1p35-p36), 2B (to 3q13-q22), and 2D (to 7p14) [1].
  • Charcot-Marie-Tooth (CMT) disease type 2 (CMT2) is an inherited peripheral neuropathy characterized by variable age of onset and normal or slightly diminished nerve conduction velocity [2].
  • The novel C59T mutation in the leader peptide of the MPZ gene is pathogenic and manifests as severe, late-onset, axonal, symmetric sensorimotor polyneuropathy (CMT2) and hyper-CK-emia [3].
  • Charcot-Marie-Tooth (CMT) disease represents a clinically and genetically heterogeneous group of inherited neuropathies caused by aberration of the intimate relationship between the myelin sheath and the axon; disorders causing demyelination are classified as CMT1 and those causing axonal loss as CMT2 [4].

Psychiatry related information on MAD2L1BP

  • In a series of 44 consecutive patients with Charcot-Marie-Tooth disease (CMT), we found restless legs syndrome (RLS) in 10 of 27 CMT type 2 (CMT2) patients (37%) and in none of 17 CMT type 1 patients (p = 0.004) [5].

High impact information on MAD2L1BP


Biological context of MAD2L1BP

  • Our data suggest that P0 mutations account for a detectable proportion of CMT2 cases with virtually every patient harbouring a different mutation but recurrence of the Thr124Met amino acid substitution [8].
  • Still other mutations cause a neuropathy that presents in adults, with normal nerve conduction velocities, designated as a 'CMT2' form of CMT1B [9].
  • In this study we report a multigenerational Russian family with autosomal dominant CMT2 and assign the locus to chromosome 7q11-q21 [10].
  • These findings suggest that the CMT2 phenotype is secondary to at least two different genes and demonstrate further heterogeneity in the CMT phenotype [2].
  • Additional SNAP and SNCV evaluation may be helpful in focusing molecular genetic analysis in the occasional case of CMT2 showing slow motor nerve conduction velocities overlapping with CMT1A values [11].

Anatomical context of MAD2L1BP

  • Median nerve motor nerve conduction velocities (MNCV) were always less than 38 m/s in CMT1A patients, whereas this was also the case in 16% of the CMT2 patients [11].
  • Future work on CMT2 should produce insight not only into the cellular interactions of the peripheral nerve especially Schwann cell and axon relationships, but also into idiopathic neuropathy [12].
  • The mechanisms by which mutations disturb the relationship of the myelin sheath and axon are not fully understood; however, we hypothesize that some mutations affect this relationship more profoundly than others, and thus account for the paradox that mutation of a "myelin gene" can present with electrophysiologic features of CMT2 and vice versa [4].

Associations of MAD2L1BP with chemical compounds

  • Assessment of cell viability by means of the MTT assay demonstrated a potent dose-dependent cytotoxic effect induced by compound CMT-3 and a less potent effect induced by doxycycline, but no apparent cytotoxic effect in the presence of either CMT-2 or CMT-5 [13].

Other interactions of MAD2L1BP

  • Here we report the characterization of a novel MAD2-binding protein, CMT2 [7].


  1. Hereditary motor and sensory neuropathy type 2C is genetically distinct from types 2B and 2D. Nagamatsu, M., Jenkins, R.B., Schaid, D.J., Klein, D.M., Dyck, P.J. Arch. Neurol. (2000) [Pubmed]
  2. Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Ben Othmane, K., Middleton, L.T., Loprest, L.J., Wilkinson, K.M., Lennon, F., Rozear, M.P., Stajich, J.M., Gaskell, P.C., Roses, A.D., Pericak-Vance, M.A. Genomics (1993) [Pubmed]
  3. Novel C59T leader peptide mutation in the MPZ gene associated with late-onset, axonal, sensorimotor polyneuropathy. Finsterer, J., Miltenberger, G., Rauschka, H., Janecke, A. Eur. J. Neurol. (2006) [Pubmed]
  4. The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy. Boerkoel, C.F., Takashima, H., Lupski, J.R. Current neurology and neuroscience reports. (2002) [Pubmed]
  5. Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Gemignani, F., Marbini, A., Di Giovanni, G., Salih, S., Terzano, M.G. Neurology (1999) [Pubmed]
  6. Conformation-specific binding of p31(comet) antagonizes the function of Mad2 in the spindle checkpoint. Xia, G., Luo, X., Habu, T., Rizo, J., Matsumoto, T., Yu, H. EMBO J. (2004) [Pubmed]
  7. Identification of a MAD2-binding protein, CMT2, and its role in mitosis. Habu, T., Kim, S.H., Weinstein, J., Matsumoto, T. EMBO J. (2002) [Pubmed]
  8. Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible "hotspot" on Thr124Met. Senderek, J., Hermanns, B., Lehmann, U., Bergmann, C., Marx, G., Kabus, C., Timmerman, V., Stoltenburg-Didinger, G., Schröder, J.M. Brain Pathol. (2000) [Pubmed]
  9. Phenotypic clustering in MPZ mutations. Shy, M.E., Jáni, A., Krajewski, K., Grandis, M., Lewis, R.A., Li, J., Shy, R.R., Balsamo, J., Lilien, J., Garbern, J.Y., Kamholz, J. Brain (2004) [Pubmed]
  10. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Ismailov, S.M., Fedotov, V.P., Dadali, E.L., Polyakov, A.V., Van Broeckhoven, C., Ivanov, V.I., De Jonghe, P., Timmerman, V., Evgrafov, O.V. Eur. J. Hum. Genet. (2001) [Pubmed]
  11. Comparison of CMT1A and CMT2: similarities and differences. Bienfait, H.M., Verhamme, C., van Schaik, I.N., Koelman, J.H., de Visser, B.W., de Haan, R.J., Baas, F., van Engelen, B.G., de Visser, M. J. Neurol. (2006) [Pubmed]
  12. Charcot-Marie-Tooth disease type 2. Vance, J.M. Ann. N. Y. Acad. Sci. (1999) [Pubmed]
  13. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells. Bettany, J.T., Wolowacz, R.G. Adv. Dent. Res. (1998) [Pubmed]
WikiGenes - Universities